Abstract
The pharmacological agent 1-(2-Chlorophenyl-N-methylpropyl)-3-isoquinolinecarboxamide (PK11195) is the prototypical ligand of the 18-kDa Translocator Protein (TSPO) but at μM concentrations deactivates the oncoprotein Bcl-2 increasing the efficiency of chemotherapeutic agents and promoting the Ca2+-dependent macro-autophagy (or autophagy).
In this paper, we report that PK11195, in HeLa cells, modifies the mitochondria-targeted type of autophagy - hereafter referred to as mitophagy- and the associated resizing of the mitochondrial network but does so exclusively in absence of the oncoprotein Bcl-2 (Bcl-2 Kd cells).
This is consequence of a “side” targeting of the mitochondrial F1Fo-ATPsynthase enzyme, since identical outcome is mimicked by the antibiotic Oligomycin, of which PK11195 matches the effect on: i) mitochondrial membrane potential (ΔΨm), ii) ATP homeostasis and iii) Reactive Oxygen Species (ROS) generation.
Taken together, these data highlight a novel TSPO-independent biological effect for PK11195 and provide evidences for a hitherto uncovered Bcl-2-dependent role of the F1Fo-ATPsynthase in mitochondrial quality control.
Keywords: Bcl-2, F1Fo-ATPsynthase, mitophagy, PK11195
Current Molecular Medicine
Title:PK11195 Inhibits Mitophagy Targeting the F1Fo-ATPsynthase in Bcl-2 Knock-Down Cells
Volume: 12 Issue: 4
Author(s): M. S.D. Seneviratne, D. Faccenda, V. De Biase and M. Campanella
Affiliation:
Keywords: Bcl-2, F1Fo-ATPsynthase, mitophagy, PK11195
Abstract: The pharmacological agent 1-(2-Chlorophenyl-N-methylpropyl)-3-isoquinolinecarboxamide (PK11195) is the prototypical ligand of the 18-kDa Translocator Protein (TSPO) but at μM concentrations deactivates the oncoprotein Bcl-2 increasing the efficiency of chemotherapeutic agents and promoting the Ca2+-dependent macro-autophagy (or autophagy).
In this paper, we report that PK11195, in HeLa cells, modifies the mitochondria-targeted type of autophagy - hereafter referred to as mitophagy- and the associated resizing of the mitochondrial network but does so exclusively in absence of the oncoprotein Bcl-2 (Bcl-2 Kd cells).
This is consequence of a “side” targeting of the mitochondrial F1Fo-ATPsynthase enzyme, since identical outcome is mimicked by the antibiotic Oligomycin, of which PK11195 matches the effect on: i) mitochondrial membrane potential (ΔΨm), ii) ATP homeostasis and iii) Reactive Oxygen Species (ROS) generation.
Taken together, these data highlight a novel TSPO-independent biological effect for PK11195 and provide evidences for a hitherto uncovered Bcl-2-dependent role of the F1Fo-ATPsynthase in mitochondrial quality control.
Export Options
About this article
Cite this article as:
S.D. Seneviratne M., Faccenda D., De Biase V. and Campanella M., PK11195 Inhibits Mitophagy Targeting the F1Fo-ATPsynthase in Bcl-2 Knock-Down Cells, Current Molecular Medicine 2012; 12 (4) . https://dx.doi.org/10.2174/1566524011207040476
DOI https://dx.doi.org/10.2174/1566524011207040476 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
Call for Papers in Thematic Issues
Molecular and Cellular Mechanisms in Vertigo / Vestibular Disorders
Vertigo and vestibular diseases are common among middle-aged and older adults, significantly increasing the risk of falls and leading to injuries and disabilities. Despite their prevalence, therapeutic advancements are hindered by a limited understanding of the underlying molecular and cellular mechanisms. This Special Issue is dedicated to bridging this gap ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The PI3 Kinase Signaling Pathway in Prostate Cancer
Current Cancer Drug Targets Lipid Nanoparticles to Deliver miRNA in Cancer
Current Pharmaceutical Biotechnology The Origin and Identification of Mesenchymal Stem Cells in Teeth: from Odontogenic to Non-odontogenic
Current Stem Cell Research & Therapy Structure-Activity Relationship of Supramolecular Compounds in Drug Delivery
Mini-Reviews in Organic Chemistry Synthetic 2-Methoxyestradiol Derivatives: Structure-Activity Relationships
Current Medicinal Chemistry Synthesis and Anti – Tumour Activity of Novel Camptothecin – Bile Acid Analogues
Letters in Drug Design & Discovery Genetic and Epigenetic Studies for Determining Molecular Targets of Natural Product Anticancer Agents
Current Cancer Drug Targets Rediscovering Tocophersolan: A Renaissance for Nano-Based Drug Delivery and Nanotheranostic Applications
Current Drug Targets CD40L - A Multipotent Molecule for Tumor Therapy
Endocrine, Metabolic & Immune Disorders - Drug Targets A Lesion based and Sub-regional Comparison of FDG PET/CT and MDP Bone Scintigraphy in Detection of Bone Metastasis in Breast Cancer
Current Medical Imaging Chemotherapeutic Effects of Acridine Derivatives
Medicinal Chemistry Reviews - Online (Discontinued) Development and Challenges of Synthetic Retinoid Formulations in Cancer
Current Drug Delivery Chemoprevention of Breast Cancer by Dietary Compounds
Anti-Cancer Agents in Medicinal Chemistry Roles of Tumor Microenvironment in Hepatocelluar Carcinoma
Current Cancer Therapy Reviews Expression of HPV 58 Long and Short L1 Capsid Proteins in Primary Mouse Keratinocyte Cultures
Protein & Peptide Letters Recent Applications of Azo Dyes: A Paradigm Shift from Medicinal Chemistry to Biomedical Sciences
Mini-Reviews in Medicinal Chemistry Formulation, Pharmacokinetic Evaluation and Cytotoxicity of an Enhanced- penetration Paclitaxel Nanosuspension
Current Cancer Drug Targets Cervical Cancer Therapeutics: An In-depth Significance of Herbal and Chemical Approaches of Nanoparticles
Anti-Cancer Agents in Medicinal Chemistry Design of Magnetic Nanoparticles-Assisted Drug Delivery System
Current Pharmaceutical Design Role of the heme oxygenase-adiponectin-atrial natriuretic peptide axis in renal function
Current Pharmaceutical Design